非酒精性脂肪性肝炎 (NASH) 治療、診斷的全球市場:2020∼2027年
Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market - 2020-2027
非酒精性脂肪性肝炎 (NASH) ，是造成纖維症的胰島素抗性強的相關聯的慢性肝疾病一般原因。第二型糖尿病和非酒精性脂肪性肝疾病 (NAFLD)通常並存。根據National Institutes of Health (NIH) ，在第二型糖尿病患者中2018年的NAFLD的盛行率約60.0％。因此，糖尿病的發生率和盛行率的上升，帶給非酒精性脂肪性肝炎的治療及診斷市場大幅可能性。
本報告提供全球非酒精性脂肪性肝炎 (NASH) 治療、診斷市場相關調查分析，市場概要，市場成長的影響要素，各市場區隔、各地區的市場規模和與前一年同期比較成長，及主要企業等相關分析。
Non-alcoholic steatohepatitis (NASH) is a common cause of chronic liver disease strongly associated with insulin resistance leading to fibrosis. Type 2 diabetes and NAFLD commonly exist together. The NAFLD comprises simple steatosis (NAFL), non-alcoholic steatohepatitis, and cirrhosis. According to the National Institute of Health, in 2018, NAFLD has a prevalence of around 60.0% among type 2 diabetes patients. Hence the rising incidence and prevalence rate of diabetes creates significant scope for the non-alcoholic steatohepatitis therapeutics and diagnostics market.
The global non-alcoholic steatohepatitis therapeutics and diagnostics market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
The rising prevalence of non-alcoholic steatohepatitis and the high prevalence of liver-related diseases are some factors that are expected to propel the market growth. Furthermore, the government support through programs and initiatives and the continuous ongoing research for non-alcoholic steatohepatitis biomarker supports the growth of the market across the globe.
Government support through programs and initiatives is driving the growth of the global market
The increasing number of programs and initiatives taken by the organizations to develop non-alcoholic steatohepatitis drugs and diagnostic tools significantly drives the growth of the market. For instance, biopharmaceutical company GENFIT in 2016 has taken an initiative "The non-alcoholic steatohepatitis Education Program" for creating awareness about non-alcoholic steatohepatitis among patients. GENFIT also started the Pediatric NAFLD/non-alcoholic steatohepatitis Program in Europe after approval of the elafibranor's Pediatric Investigation Plan by the European Medicine Agency in 2016. This is projected to facilitate the drug development program in the future.
Research for non-alcoholic steatohepatitis biomarker will continue supporting the growth of the market during the forecast period
Increasing research activities to raise the already available biomarkers' productivity and efficiency or discover new ones are expected to create enormous opportunities for the non-alcoholic steatohepatitis market growth. The prevalence of non-alcoholic steatohepatitis across the globe is increasing dramatically, which is driving the requirement of various diagnosis methods. The current method for the diagnosis of non-alcoholic steatohepatitis includes live biopsy, which is an invasive procedure. Although liver biopsy is still considered the most reliable standard method for diagnosing non-alcoholic steatohepatitis, however, it can lead to various clinical complications such as trauma and bleeding.
COVID-19 Impact Analysis
The COVID-19 pandemic has hampered the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market. Though the risk for the occurrence of COVID-19 is considerably high in patients suffering from non-alcoholic steatohepatitis, the new diagnosis and treatments have declined amidst the crisis. Moreover, the ongoing research in research institutes and other private organizations have reduced due to a diversion in the R&D of the COVID-19 vaccine. Therefore, the demand for non-alcoholic steatohepatitis therapeutics and diagnostics is expected to decrease the growth to the market value in 2020.
Based on the diagnostics, the non-alcoholic steatohepatitis therapeutics and diagnostics market has been classified into imaging techniques, diagnostic tests, and biopsy.
Diagnostic Tests segment dominated the global non-alcoholic steatohepatitis therapeutics and diagnostics market in 2019
There are only a few diagnostic tests available for the diagnosis of non-alcoholic steatohepatitis, which includes liver function tests, lipid profile tests, and fibrosis assessment tests. The presence of non-alcoholic steatohepatitis is confirmed when the diagnostic results of the tissue shows fat, inflammation, and damage to liver cells. Moreover, several in-vitro diagnostics test set to be released in 2021, which will support the segmental growth across the globe. Therefore, diagnostic tests contribute a major share in the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market across the globe.
Based on the therapeutics, the non-alcoholic steatohepatitis therapeutics and diagnostics market has been classified into Ocaliva, Elafibranor, Cenicriviroc, Selonsertib, and others.
Selonsertib segment accounted for the highest market share in the global market
Selonsertib for patients with linking fibrosis or compensated cirrhosis due to non-alcoholic steatohepatitis. It is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with likely anti-inflammatory, antineoplastic, and anti-fibrotic activities. Selonsertib targets and ties to the catalytic kinase domain of ASK1 in an ATP-competitive approach; by this means, preventing its phosphorylation and activation. Therefore, Selonsertib contributes a considerable share in the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market across the globe.
Based on geography, the study analyzes the non-alcoholic steatohepatitis therapeutics and diagnostics market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America dominated the global non-alcoholic steatohepatitis therapeutics and diagnostics market and is expected to retain its position during the forecast period. The US contributed over 82.0% in the North American non-alcoholic steatohepatitis therapeutics and diagnostics market in 2019. The primary factor contributing to the growth of the market includes the significant funding provided by government organizations and pharmaceutical companies for the R&D of biomarkers. The presence of sophisticated healthcare amenities, the growing incidence of diabetes, obesity, and fatty liver disease are supporting the growth of the target market in this region.
The Asia Pacific is estimated to grow at a considerable growth rate in the non-alcoholic steatohepatitis therapeutics and diagnostics market during the forecast period. The growth of Asia-Pacific is mainly attributed to the rapidly evolving healthcare infrastructure coupled with increasing awareness of chronic liver conditions across the region. Moreover, the expansion of foreign market players in the nation's emerging economies, such as China and India.
The non-alcoholic steatohepatitis therapeutics and diagnostics market is highly competitive. The key non-alcoholic steatohepatitis therapeutics and diagnostics players that are contributing to the growth of the global market include Cadila Healthcare Limited, Genfit SA, Gilead Sciences Inc., Novo Nordisk A/S, Quest Diagnostics, Shire Plc, Siemens Healthineers, Thermo Fisher Scientific Inc. The major players are adopting new product launch and expansion strategies for global growth in the non-alcoholic steatohepatitis therapeutics and diagnostics market.
Overview: Quest Diagnostics was established in 1967 and is headquartered in Secaucus, the US. The company offers diagnostic testing, services, and information. The company serves in a national network of full-service laboratories, patient services centers, and rapid response laboratories. The company provides routine medical, drug abuse, esoteric, and non-hospital-based anatomic pathology testing services. The company is a provider of pre-employment drug abuse screening for risk assessment services for the life insurance industry. The company operates in cancer diagnostics, anatomic pathology services, healthcare information technology solutions, diagnostic testing information and services, gene-based testing, and clinical testing.
Product Portfolio: For diagnosis of non-alcoholic steatohepatitis, the company offers non-alcoholic steatohepatitis fibrosure. NASH fibrosure test provides a non-invasive assessment of liver status in patients with non-alcoholic fatty liver disease (NAFLD).
The global non-alcoholic steatohepatitis therapeutics and diagnostics market report would provide access to an approx. 70 market data tables, 60 figures, and 279 pages.
LIST NOT EXHAUSTIVE